Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GE Healthcare to Invest in Oncology Solutions | Contract Pharma

What are you searching for?

Sign in
Breaking News

GE Healthcare to Invest in Oncology Solutions

To dedicate $1 billion of R&D budget to expand capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GE Healthcare plans to dedicate $1 billion of its R&D budget during the next five years to expand its cancer diagnostic and molecular imaging capabilities, as well as its technologies for the manufacture of biopharmaceuticals and cancer research.

The investment is aimed at enabling GE to bring the most promising cancer ideas to market using technologies that improve accuracy of diagnosis to enable more effective treatment decisions.

“We are committed to tackling cancer. However, with a disease as complex and multifaceted as cancer, solutions need to be equally multifaceted and even more integrated, combining imaging, molecular diagnostics and healthcare IT,” said John Dineen, president and chief executive officer, GE Healthcare. “As one of the most relevant global cancer diagnostic companies, we are devoting an even greater share of our R&D budget to continue developing new oncology solutions.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics